0001922451-22-000001.txt : 20220414 0001922451-22-000001.hdr.sgml : 20220414 20220414144341 ACCESSION NUMBER: 0001922451-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 EFFECTIVENESS DATE: 20220414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Salish Bioscience Inc. CENTRAL INDEX KEY: 0001922451 IRS NUMBER: 871401228 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-441884 FILM NUMBER: 22826897 BUSINESS ADDRESS: STREET 1: 13021 13TH AVE NW CITY: SEATTLE STATE: WA ZIP: 98177-4110 BUSINESS PHONE: 2068496038 MAIL ADDRESS: STREET 1: 13021 13TH AVE NW CITY: SEATTLE STATE: WA ZIP: 98177-4110 D 1 primary_doc.xml X0708 D LIVE 0001922451 Salish Bioscience Inc. 3005 1st Avenue Suite 204 SEATTLE WA WASHINGTON 98121 2068496038 WASHINGTON None None Corporation true 2021 Frank Paganelli 3005 1st Avenue Suite 204 Seattle WA WASHINGTON 98121 Executive Officer Director Kira Misura 3005 1st Avenue Suite 204 Seattle WA WASHINGTON 98121 Director Chris Raymond 3005 1st Avenue Suite 204 Seattle WA WASHINGTON 98121 Director Fenella Raymond 3005 1st Avenue Suite 204 Seattle WA WASHINGTON 98121 Executive Officer Director Other Health Care Decline to Disclose 06b false 2022-03-31 false true true Series Seed Preferred Stock and conversion of notes false 0 7037397 7037397 0 Total amount sold is comprised of a cash amount equal to $6,000,000 plus $1,037,397 upon conversion of existing convertible notes. false 25 0 0 0 false Salish Bioscience Inc. /s/ Frank Paganelli Frank Paganelli Chief Executive Officer 2022-04-13